Celgene and Human Genome Might Marry and 4 Analyst Insights
KLA-Tencor Corporation (NASDAQ:KLAC) possesses the largest downside in the risk due to higher relative valuation and notes many stocks are pricing in order weakness, according to Goldman. The firm gives shares a Neutral rating.
Celgene Corporation (NASDAQ:CELG): Following Reuters’ report that Celgene had become a possible second bidder for the acquisition of Human Genome Sciences (NASDAQ:HGSI), Rodman & Renshaw vocalized that the move would be somewhat irrational for Celgene. The firm states that shareholders of Celgene would not have much tolerance for the sizable and possibly dilutive acquisition. Rodman & Renshaw maintains an Outperform rating with a $76 price target on the shares.
PMFG, Inc. (NASDAQ:PMFG): According to Stifel Nicolause, the company’s selling pressure on stock throughout the past three months is “largely unrelated” to PMFG’s fundamentals, the firm believes the company’s orders will rise during the next few quarters. The firm keeps a Buy rating and $21 price target on the shares.
SunCoke Energy, Inc (NYSE:SXC): Goldman states that its favorite coal stocks, including; SunCoke Energy (NYSE:SXI), Peabody Energy (NYSE:PBY), and CONSOL Energy (NYSE:CNX), are oversold due to concerns about domestic thermal coal demand as well as global growth. The firm keeps its Buy rating and its Attractive view on the sector.
Varian Medical Systems Inc. (NYSE:VAR) should be purchased on any weakness after the CMS proposals to reduce 2013 reimbursement for radiation as well as proton therapy. The firm states that although the cuts were proposed, there are other opportunities which could be favorable to the company. The firm gives the shares an Outperform rating with a &71 price target.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.